Tag: nasdaq:cala

March 26, 2019

Calithera Biosciences Initiates Phase 1/2 Trial of Telaglenastat in Combination with the PARP Inhibitor Talazoparib

Calithera Biosciences (NASDAQ:CALA) has announced the first patietn has been treated in its Phase 1/2 open-label clinical trial of the...
October 5, 2018

Calithera Biosciences Announces Clinical Trial Collaboration to Evaluate IBRANCE (palbociclib) and talazoparib in Combination with CB-839

Calithera Biosciences (Nasdaq:CALA), a clinical stage biotechnology company focused on the development of novel cancer therapeutics, today announced two new...